Fellowship · Charleston, SC
Sponsored by Medical University of South Carolina College of Medicine
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nature medicine · 2023 · 266 citations · Maxim Yankelevich
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 212 citations · Prakash Satwani
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
The New England journal of medicine · 2022 · 172 citations · Jennifer Jaroscak
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.
The New England journal of medicine · 2026 · 16 citations · Jennifer Jaroscak
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 58 citations · Jacqueline Kraveka
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy.
Blood advances · 2022 · 108 citations ·
Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience.
Pediatric blood & cancer · 2021 · 90 citations · Prakash Satwani
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy.
Nature cancer · 2024 · 55 citations · Christina New